Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer
Sammanfattning
Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the
past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The
continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic
vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines
and discusses the impact on future CRPC management.